The COVID-19 pandemic will have a significant impact on the US diagnostic imaging market in the short term. Once the market stabilizes, however, the contrast agents and radiopharmaceuticals market in US will see modest growth through 2029 driven by a growing aging population, increases in health risk factors like poor lifestyle, and adoption of new technology due to favorable regulatory changes. However, overall market expansion will be hindered by a saturated installed base of large imaging systems as well as consolidation of hospitals.
Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities, while the shift to value-based care will hinder the use of some procedures while supporting the use of those that provide the most accuracy and clarity of visualization.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in the US across a 10-year period.
The COVID-19 pandemic will affect the diagnostic imaging system market.
To what extent will the COVID-19 pandemic impact the US diagnostic imaging system market?
How will the impact of the COVID-19 pandemic differ between segments?
How quickly are procedure volumes expected to rebound?
The FDA recently expanded approval for the use of CEUS in radiology procedures.
What types of procedures does this approval extend to? Which additional procedures could be approved in the future?
Which contrast agents received FDA approval?
How will competitors that do not have FDA approval react?
Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.
How are ACOs, health networks, and physicians responding to the recent findings on gadolinium retention?
What are the key differences between linear and macrocyclic GBCAs, and how will market demand for these products shift going forward?
Will other imaging modalities cannibalize contrast-enhanced MRI procedures?
While less concerning than in the past, radiation dose concerns still exert a limiting effect on procedure volumes for some imaging modalities.
How are US radiologists responding, and what methods are they using to ensure image quality?
Which procedures are being cannibalized by other modalities that do not require radiation for image acquisition?
The SPECT radiopharmaceuticals industry is taking precautionary measures to insulate itself from the shortening supply of Mo-99 and Tc-99.
What novel technology is showing promise that could help with global supply of Tc-99?
How will the transition from HEU to LEU reactors affect ASPs in the US market?
- Contrast Agents And Radiopharmaceuticals - Market Insights - United States
Author(s): Benny Jacob, MS
Benny Jacob is an analyst on the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in the ENT Devices market. Benny has a background that covers Data Science, Systems Neuroscience and Bioinformatics. Benny has a Masters' Degree in Computational Biology from Carnegie Mellon University, Pittsburgh and a Bacherlor's Degree in Biotechnology from Manipal Institute of Technology, Manipal (India).